Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as INS50589 Intravenous Infusion
INS50589 Infusion · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| INS50589 Intravenous Infusion | DRUG | - |
Inclusion Criteria: * Have body mass index (BMI) between 18.5 kg/m2 and 35 kg/m2 and body weight no greater than 120 kg. * If female, must not be pregnant or lactating, and if of childbearing potential or sexually active, must use acceptable method of birth control. Exclusion Criteria: * Have cli...
Top 4 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Lepodisiran |
| Illumina, Inc. | ILMN | 1 | PHASE1 | 18F-mFBG for administration |
INS50589 Infusion is an investigational small molecule developed by Merck & Company, Inc. (MRK) for cardiovascular disease. It is administered as an intravenous infusion and has been studied in a Phase 1 clinical trial in healthy volunteers. It is not approved and remains in clinical development.
INS50589 Infusion is being developed for cardiovascular disease. The only reported clinical study enrolled healthy volunteers rather than patients, so the program is at an early research stage and no approved use exists. It is an investigational agent, not a marketed therapy.
INS50589 Infusion is developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck sponsored the Phase 1 study of the intravenous infusion in healthy volunteers conducted in the United States.
INS50589 Infusion is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The program has not advanced beyond early clinical testing, and the drug is investigational rather than approved for any indication.
INS50589 Infusion has been studied in one completed Phase 1 trial, NCT00099450, titled Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers. It enrolled 48 healthy adult participants of all sexes in the United States. No trials are currently active.
Yes. INS50589 Infusion and INS50589 Intravenous Infusion refer to the same investigational Merck compound. The intravenous infusion name reflects the route of administration used in the Phase 1 study NCT00099450, which evaluated tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.